ライフサイエンスコーパス: EGF receptor

1 tive interdomain pocket of the extracellular EGF receptor.

2 umor lesions through active targeting of the EGF receptor.

3 verse growth factor receptors, including the EGF receptor.

4 ation of the growth factor receptors Met and EGF receptor.

5 es or on endocytosis-mediated degradation of EGF receptor.

6 ory role of CD82 in endocytic trafficking of EGF receptor.

7 increased EGF-induced phosphorylation of the EGF receptor.

8 ce and depends on the kinase activity of the EGF receptor.

9 phorylated and associated with the activated EGF receptor.

10 B domain of Shc (SHC adaptor protein) to the EGF receptor.

11 rlotinib, a clinically used inhibitor of the EGF receptor.

12 ion of the receptor tyrosine kinases MET and EGF receptor.

13 h direct binding and activation of the renal EGF receptor.

14 he binding of Grb2 and Shc to the single-Tyr EGF receptors.

15 d signaling via the epidermal growth factor (EGF) receptor.

16 yr kinase domain of epidermal growth factor (EGF) receptor.

17 tyrosine-protein kinase erbB-2 (ERBB2)/human EGF receptor 2 (HER2), and, to a lesser extent, ERBB4/HE

18 or to an affibody directed against the human EGF receptor 2 (HER2).

19 l Growth Factor Receptors (EGFR) or to human EGF receptors 2 (HER2), which are overexpressed in sever

20 ispecific antibody MCLA-128, targeting human EGF receptors 2 and 3.

21 ates with another kinase, called HER2 (human EGF-receptor 2), we assumed that agents targeting EGFR a

22 nter on invading the uterus increased HLA-G, EGF-Receptor-2, and LIF-Receptor expression on EVT, pres

23 Furthermore, the EGF receptor-3 protein localizes asymmetrically on the c

24 horylated downstream of protein kinase C and EGF receptor activation and is a substrate for protein k

25 rk analysis highlighted the central role for EGF receptor activation in mediating the observed respon

26 were strongly reduced, resulting in reduced EGF receptor activation in the cancer cells.

27 imer formation, suggesting that its path for EGF receptor activation involves binding to both monomer

28 ough spatiotemporally regulated responses to EGF receptor activation.

29 H3 and phosphorylates histone H3 at T11 upon EGF receptor activation.

30 tered downstream of epidermal growth factor (EGF) receptor activation, following the phosphorylation

31 ferences in network utilization by different EGF receptor agonists and highlight the need to characte

32 cargos, such as the epidermal growth factor (EGF) receptor, along the endocytic pathway.

33 otein/extracellular signal-regulated kinase, EGF receptor and ADAM17 activity.

34 require the tyrosine kinase activity of the EGF receptor and are mediated by complexes containing ac

35 l sulfate and p-cresol sulfate activated the EGF receptor and downstream signaling by enhancing recep

36 racterized the interaction of ErbB3 with the EGF receptor and ErbB2 and assessed the effects of Food

37 ble of compensatory PI3K signaling from both EGF receptor and ErbB2.

38 ch was accompanied by transactivation of the EGF receptor and ERK1/2 phosphorylation.

39 Silencing messenger RNAs and blocking EGF receptor and IL15 antibodies have been used to study

40 samples from patients with CD was reduced by EGF receptor and IL15 blocking antibodies only when used

41 ol sulfate significantly activated the renal EGF receptor and increased the tubulointerstitial expres

42 re an active block to signal transduction by EGF receptor and LIN-12/Notch and have a different mecha

43 epidermal growth factor (EGF) share the same EGF receptor and previously indistinguishable intracellu

44 eptor tyrosine kinase acts downstream of the EGF receptor and Src tyrosine kinases to promote invadop

45 Mature ECs lack EGF receptors and are refractory to growth signalling.

46 icrobiome-derived, metabolite levels through EGF receptors and downstream signaling to induce their s

47 isintegrin and metalloprotease 17) regulates EGF-receptor and TNFalpha signaling, thereby not only pr

48 a leads to aberrant activation of TAK1, JNK, EGF receptor, and ERK in distinct microanatomical areas

49 olonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies.

50 ronectin interactions on the efficacy of the EGF receptor antibody cetuximab, which is used widely fo

51 nd is associated with enhanced and prolonged EGF receptor autophosphorylation.

52 mice administered cetuximab, an inhibitor of EGF receptor binding, and (b) immunological data showing

53 se to certain growth factor receptors (i.e., EGF-receptor but not insulin receptor) and pathogen reco

54 The EGF receptor can bind seven different agonist ligands.

55 uently, we analyzed changes in expression of EGF receptors, cell aspect ratio, and protrusive activit

56 hages to the tumor and facilitating CSF1 and EGF receptor cross-talk between cancer cells and macroph

57 fficking to LAMP-2-positive compartments and EGF receptor degradation.

58 n of matrix metalloproteinases 2 and 9 in an EGF receptor-dependent manner.

59 a with significantly better survival, and an EGF receptor-deregulated subclass of colon cancers.

60 Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the p

61 The role of endocytosis in the control of EGF receptor (EGFR) activation and cell signaling was ex

62 Simultaneous activation of the EGF receptor (EGFR) and a thrombin receptor (protease-ac

63 ity was accompanied by reduced expression of EGF receptor (EGFR) and an increased degradation rate of

64 geting of prominent cancer antigens, such as EGF receptor (EGFR) and c-MET, by bsAbs has raised incre

65 ion of its chloride-channel activity reduced EGF receptor (EGFR) and calmodulin-dependent protein kin

66 Here, we show that the EGF receptor (EGFR) and HER2 function cooperatively to i

67 phosphorylation of specific tyrosines in the EGF receptor (EGFR) and in inefficient activation of the

68 Here, we report that the oncogenic EGF receptor (EGFR) and its inhibitors reprogram phospho

69 EGF receptor (EGFR) and MET (the receptor tyrosine kinas

70 Hyperactive EGF receptor (EGFR) and mutant p53 are common genetic ab

71 versus sustained signaling downstream of the EGF receptor (EGFR) and NGF receptor (TrkA).

72 n that MUC1-C, in turn, forms complexes with EGF receptor (EGFR) and promotes EGFR-mediated activatio

73 racellular domain of NRP1 interacts with the EGF receptor (EGFR) and promotes its signaling cascade e

74 In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contri

75 ed by temporal compensatory increases in the EGF receptor (EGFR) and the hepatocyte growth factor rec

76 odimeric IgG derived from anti-HER2 and anti-EGF receptor (EGFR) antibody was shown to induce a highe

77 sine kinase inhibitors (TKI) that target the EGF receptor (EGFR) are effective in most non-small cell

78 I-1757 inhibits STAT3 dimerization and STAT3-EGF receptor (EGFR) binding in intact cells.

79 ternalization and partial degradation of the EGF receptor (EGFR) by the endo-lysosomal pathway.

80 nctions as a tumor suppressor that restricts EGF receptor (EGFR) cell surface occupancy as well as Ak

81 udy a mechanism by which dimerization of the EGF receptor (EGFR) cytoplasmic domain is transmitted to

82 tive late endosomes and lysosomes and slowed EGF receptor (EGFR) degradation.

83 Stress exposure triggers ligand-independent EGF receptor (EGFR) endocytosis, but its post-endocytic

84 sponse to LPS is impaired by down regulating EGF receptor (EGFR) expression or by using the EGFR inhi

85 Because TNBC commonly displays EGF receptor (EGFR) expression, and combinations of mono

86 The EGF receptor (EGFR) family comprises four homologs in hu

87 ErbB3 (HER3) is a member of the EGF receptor (EGFR) family of receptor tyrosine kinases,

88 en by signature genetic alterations, such as EGF receptor (EGFR) gene amplification and mutation, pla

89 ive with amplification and expression of the EGF receptor (EGFR) gene.

90 Tyrosine kinase inhibitors (TKIs) of the EGF receptor (EGFR) have provided a significant improvem

91 The EGF receptor (EGFR) HER3 is emerging as an attractive ca

92 e ligands on subunit-subunit interactions in EGF receptor (EGFR) homodimers and EGFR/ErbB2 heterodime

93 s barrier function by transactivation of the EGF receptor (EGFR) in intestinal epithelial cells.

94 Sustained activation of EGF receptor (EGFR) in proximal tubule cells is a hallma

95 dying enterocyte triggers activation of the EGF receptor (Egfr) in stem cells within a discrete radi

96 EGF receptor (EGFR) inhibition is efficacious in cancer

97 C cell proliferation, which is enhanced with EGF receptor (EGFR) inhibition.

98 We therefore examined the effects of the EGF receptor (EGFR) inhibitor erlotinib on liver fibroge

99 Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical developme

100 ening assay prompted us to determine whether EGF receptor (EGFR) inhibitors stimulate AQP2 traffickin

101 ficient to heighten therapeutic responses to EGF receptor (EGFR) inhibitors.

102 role in the trafficking of the ligand-bound EGF receptor (EGFR) internalized through receptor-mediat

103 In this study we show that EGF receptor (EGFR) is activated following pemphigus vul

104 The EGF receptor (EGFR) is amplified and mutated in glioblas

105 dermal growth factor (EGF) activation of the EGF receptor (EGFR) is an important mediator of cell mig

106 Ligand-induced ubiquitylation of EGF receptor (EGFR) is an important regulatory mechanism

107 Overexpression of the EGF receptor (EGFR) is recognized as a widespread oncoge

108 The kinase activity of the EGF receptor (EGFR) is required, because the potent and

109 ously established that overexpression of the EGF receptor (EGFR) is sufficient to induce tumor format

110 The EGF receptor (EGFR) is widely expressed in the kidney in

111 The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlo

112 lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who are treated long-term wi

113 n-induced type 1 diabetes, podocyte-specific EGF receptor (EGFR) knockout mice (EGFR(podKO)) and thei

114 Recent studies have identified the EGF receptor (EGFR) ligand amphiregulin (AREG) as an imp

115 EGF receptor (EGFR) ligand and species specificities of

116 elevance of iRhom2 in regulating shedding of EGF receptor (EGFR) ligands is established by a lack of

117 leased by proteolytic cleavage, bound to the EGF receptor (EGFR) on cancer cells inducing EGFR phosph

118 or (EGF), leading to decreased activation of EGF receptor (EGFR) on target cells and, eventually, dam

119 Signaling by the EGF receptor (EGFR) or cAMP amplified the activation of

120 Activation of the EGF receptor (EGFR) or the Hippo signaling pathway can c

121 EGF receptor (EGFR) promotes tumor growth as well as rad

122 ect targets of miR-148a were identified, the EGF receptor (EGFR) regulator MIG6 and the apoptosis reg

123 face pro-EGF to HMW-EGF that stimulated HeLa EGF receptor (EGFR) reporter cells and EGFR-dependent tu

124 tumors harboring activating mutations in the EGF receptor (EGFR) show good initial treatment response

125 the role of the Tid1 isoforms in regulating EGF receptor (EGFR) signaling and lung cancer progressio

126 disintegrin and metalloprotease 17) controls EGF receptor (EGFR) signaling by liberating EGFR ligands

127 ay dependence or (ii) constitutive autocrine EGF receptor (EGFR) signaling driven by c-Jun-mediated E

128 evels of functional proteins associated with EGF receptor (EGFR) signaling in pairs of U87EGFR varian

129 Enhanced EGF receptor (EGFR) signaling is a hallmark of many huma

130 Despite extensive study of the EGF receptor (EGFR) signaling network, the immediate pos

131 Activated EGF receptor (EGFR) signaling plays an instrumental role

132 ential for the termination of EGF-stimulated EGF receptor (EGFR) signaling.

133 ollagen production through inhibition of the EGF receptor (EGFR) that phosphorylates cytoplasmic and

134 ype 1 matrix metalloproteinase (MT1-MMP) and EGF receptor (EGFR) to the cell surface during invadopod

135 Immunofluorescence showed altered EGF receptor (EGFR) trafficking, where EGFR remained mem

136 eta1-adrenergic receptor stimulation-induced EGF receptor (EGFR) transactivation in addition to Gbeta

137 Activation of EGF receptor (EGFR) triggers signaling pathways regulati

138 Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is

139 EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extrace

140 or-activated receptor, because inhibition of EGF receptor (EGFR) with cetuximab or EGF-depleted amnio

141 sly we used gene-editing to label endogenous EGF receptor (EGFR) with GFP and demonstrate that picomo

142 diated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib

143 Because Rho, EGF receptor (EGFR), and E-cad are associated with color

144 teracts with a variety of kinases (PKC, FES, EGF receptor (EGFR), and JAK3) that are activated by it,

145 SCs from wild-type mice expressed functional EGF receptor (EGFR), and systemic administration of EGF

146 Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), and V-Ki-ras2 Kirsten rat sarcoma v

147 imulates TGFbeta signaling and activates the EGF receptor (EGFR), but the relative contribution of th

148 le receptor-tyrosine kinases (RTKs), such as EGF receptor (EGFR), ErbB-2, FGF receptor (FGFR), and ma

149 r (EGF)-like ligand that signals through the EGF receptor (EGFR), in both osteoblasts and osteocytes.

150 like growth factor (HB-EGF), a ligand of the EGF receptor (EGFR), in nutrient-induced beta-cell proli

151 se tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-bas

152 ke growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified

153 Although both CC and SC expressed EGF receptor (EGFR), the EGFR-neutralizing monoclonal an

154 (HGF)/MET and epidermal growth factor (EGF)/EGF receptor (EGFR), two key signal transduction systems

155 ein (Vn) is a neuregulin-like ligand for the EGF receptor (Egfr), which is necessary for global devel

156 first six amino acids of this segment of the EGF receptor (EGFR), which lies in close association wit

157 The EGF receptor (EGFR)-directed monoclonal antibody cetuxim

158 (UTMD) could be used to enhance delivery of EGF receptor (EGFR)-directed siRNA to murine squamous ce

159 Many feedback loops are present in the EGF receptor (EGFR)-ERK network, but the mechanisms driv

160 e through modification of BC function via an EGF receptor (EGFR)-mediated mechanism.

161 and neck (HNSCC) overexpress ERBB1/EGFR, but EGF receptor (EGFR)-targeted therapies have yielded disa

162 ion as a mechanism of acquired resistance to EGF receptor (EGFR)-targeted therapies in non-small cell

163 ndent on the tyrosine kinase activity of the EGF receptor (EGFR).

164 e use luciferase fragment complementation in EGF receptor (EGFR)/ErbB2 heterodimers to probe the mech

165 the autocrine or paracrine activation of the EGF receptor (EGFR)/mitogen-activated protein/extracellu

166 ment by crawling depends on signaling by the EGF receptor (EGFR); however, this was not required for

167 FR) in tissues, we generated an sfGFP-tagged EGF receptor (EGFR-sfGFP) in Drosophila The homozygous f

168 CERT determines the signaling output of the EGF receptor (EGFR/ErbB1), which is upregulated in appro

169 ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of

170 Blockade of EGF receptors (EGFR) causes cell death.

171 trigger the release of ligands that activate EGF receptors (EGFR) on the granulosa, thereby initiatin

172 degradation of the epidermal growth factor (EGF) receptor (EGFR) after its activation and internaliz

173 Activation of the epidermal growth factor (EGF) receptor (EGFR) at the cell surface initiates signa

174 Epidermal growth factor (EGF) receptor (EGFR) has been implicated in tumor develo

175 ain shedding of the epidermal growth factor (EGF) receptor (EGFR) ligand heparin-binding EGF-like gro

176 aling proteins with epidermal growth factor (EGF) receptors (EGFR) using biotinylated EGF bound to st

177 s the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like

178 ed in testes from animals with soma-depleted EGF-Receptor (EGFR).

179 ciated pool colocalizes with transferrin and EGF receptors (EGFRs) and early endosome antigen 1, but

180 In MDA-MB-468 cells, cell surface EGF receptors (EGFRs) promote cell growth, whereas intra

181 ifference in the rates of degradation of the EGF receptor (ErbB1) and ErbB2 upon treatment of cells w

182 ur study also shows that all pairings of the EGF receptor, ErbB2, and ErbB3 form ligand-independent d

183 n of several tumor-enhancing RTKs, including EGF receptor, ErbB2, hepatocyte growth factor receptor (

184 GPER-mediated signaling, which involved the EGF receptor/ERK/c-Fos/AP1 transduction pathway, as asce

185 n promoting neurite regeneration through the EGF receptor/ERK/Fos pathway, thereby demonstrating a po

186 tidic acid increased phosphorylation of AKT, EGF receptor, ERK1/2, JNK1/2/3, and c-Jun.

187 eceptor, they bound poorly to the single-Tyr EGF receptors, even those that bound full-length Grb2 an

188 rotein (GFP)-tagged epidermal growth factor (EGF) receptor expressed in Jurkat cells with immobilized

189 throid lineage, which reveals a role for the EGF receptor family member, ErbB4, as an important media

190 ly approved targeted inhibitors of the human EGF receptor family.

191 planation for the apparent preference of the EGF receptor for dimerizing with ErbB2 and suggest that

192 In many GBMs, the EGF receptor gene (EGFR) is amplified and may be truncat

193 Accordingly, reduction in the levels of the EGF receptor gene contributes to the activation of Esrrb

194 The EGF receptor has seven different cognate ligands.

195 Aberrant expression of EGF receptors has been associated with hormone-refractor

196 The human EGF receptor (HER/EGFR) family of receptor tyrosine kina

197 R2 heterodimerizes with other members of the EGF receptor/HER/ErbB family, and the HER2-HER3 dimer fo

198 is study provides valuable insights into the EGF receptor/HER/ErbB kinase structure and interactions,

199 EGF receptor/IL15R-alpha cooperation regulates intestina

200 increased plasma membrane expression of the EGF receptor in resting cells and increased EGF-induced

201 wth factor (EGF)-dependent activation of the EGF receptor in the ALA neuron.

202 also performed to estimate the expression of EGF receptors in healed corneal tissue.

203 racer (18)F-IRS for molecular imaging mutant EGF Receptors in vitro and vivo.

204 Epidermal growth factor (EGF) receptor in HUVECs was LeY modified.

205 detect upregulated epidermal growth factor (EGF) receptor in orthotopic pancreatic xenografts using

206 tivation by mutant TRPC6, a cell-autonomous, EGF receptor-independent mechanism and a non-cell-autono

207 e signaling capabilities of these single-Tyr EGF receptors indicated that they can activate a range o

208 s lysosomal targeting and degradation of the EGF receptor, indicating that it targets host-membrane t

209 cell survival and proliferation, and active EGF receptor-induced brain tumorigenesis.

210 However, treatment of GCs with the EGF receptor inhibitor AG1478, a dominant-negative RAS,

211 genous AMF overcame the inhibitory effect of EGF receptor inhibitor gefitinib on invasive motility by

212 In addition, treatment with EGF receptor inhibitors reduced retinal vascular leakage

213 olorectal cancer or in patients resistant to EGF receptor inhibitors.

214 n of downstream effector pathways shows that EGF receptor inhibits the Hippo pathway through activati

215 The EGF receptor is a classic receptor tyrosine kinase.

216 If the EGF receptor is kinase active, this results in the phosp

217 The epidermal growth factor (EGF) receptor is a member of the ErbB family of receptor

218 mainly known as a negative regulator of the EGF receptor, is an important mediator of progesterone s

219 ated in the spatiotemporal regulation of the EGF receptor, is required for TRAIL-induced cell death i

220 tors, including the epidermal growth factor (EGF) receptor, is key to various cellular processes, suc

221 surface precursor of an alternately spliced EGF receptor isoform and that sEGFR binds to EGF with hi

222 However, if the EGF receptor kinase is kinase dead, the ErbB2 kinase is

223 appaB activated by oncogenes such as Ras and EGF receptor leads to cell-autonomous effects, abrogatin

224 Late posttransplant EGF and EGF receptor levels were reduced with erlotinib.

225 presence of a midline signal provided by the EGF receptor ligand Spitz.

226 m knockdown results in overexpression of the EGF receptor ligand vein (vn), which further activates E

227 talloprotease-mediated release of a presumed EGF receptor ligand.

228 T cells express the epidermal growth factor (EGF) receptor ligand, heparin-binding EGF (HB-EGF), with

229 erting enzyme, is the major sheddase for the EGF receptor ligands and is considered to be one of the

230 different growth factors suggests that these EGF receptor ligands fall into two major groups as follo

231 ferences in biological response to different EGF receptor ligands may result from partial agonism for

232 lar peptides (C-type natriuretic peptide and EGF receptor ligands) maintain the low level of cGMP in

233 EGF receptor ligands, which activate Rac, can promote th

234 he EGF receptor when stimulated by the seven EGF receptor ligands.

235 BTC acts via both the EGF receptor, located on NSCs, and ErbB4, located on neu

236 y and which tyrosines are required to enable EGF receptor-mediated signaling, we generated a series o

237 N-glycans restricts epidermal growth factor (EGF) receptor mobility in the plasma membrane and acts s

238 LaS3 cell lines, as well as H1975 activating-EGF receptor mutant lung cancer cell resulted in dephosp

239 lation is dependent on PDK1 and PI3K but not EGF receptor or IGF1R.

240 ta subunits was blocked by inhibition of the EGF receptor or STAT3 but not by the PI3K/AKT or MEK/ERK

241 nes were linked to the Wnt, Hippo, TGF-beta, EGF receptor, or PI3K pathways, all involved in colorect

242 o enhanced cetuximab-mediated recruitment to EGF receptor-overexpressing cancer cells.

243 Accordingly, blockade of the EGF receptor partially abrogated Dkk1-mediated hematopoi

244 nt advances in our understanding of the AREG-EGF receptor pathway and its involvement in infection an

245 is revealed that the presence of a synthetic EGF receptor peptide significantly decreased the spectro

246 t also elicited prosurvival signaling via an EGF receptor/phosphoinositide 3-kinase (PI3K) pathway.

247 ation tissue area, vascularity, and IGF1 and EGF receptor phosphorylation are increased in GM3S SNA-t

248 ransferrin from endosomes, or degradation of EGF receptor proceeds unperturbed in cells with impaired

249 ith deep-seated gliomas that overexpress the EGF receptor produced an estimate of available receptor

250 stablished that the epidermal growth factor (EGF) receptor, receptor tyrosine-protein kinase erbB-2 (

251 rbital, which is not a CAR ligand, binds the EGF receptor, reversing the EGF signal to monomerize CAR

252 s "checkpoint." Dysregulated CME also alters EGF receptor signaling and leads to constitutive activat

253 Suppression of EGF receptor signaling appeared necessary for the therap

254 breast cancer, emphasizing the importance of EGF receptor signaling in breast tumor pathogenesis and

255 Conversely, EGF receptor signaling in macrophages exacerbated inflam

256 proliferative activities along with enhanced EGF receptor signaling in the articular cartilage and in

257 NEU3 up-regulation stimulates the EGF receptor signaling pathway, which in turn activates

258 beta cells but also release EGF to activate EGF receptor signaling that inhibits TGFbeta1-activated

259 ed for SREBP-1 activation by angiotensin II, EGF receptor signaling was necessary for activation of t

260 rTMD1 inhibited EGF receptor signaling, chemotaxis, and tube formation i

261 reased expression of gene pathways mediating EGF receptor signaling, circadian exercise, striated mus

262 gulated kinases 1 and 2 (MEK/ERK1/2) and (b) EGF receptor signaling.

263 gene within bract cells of the pupal leg by EGF receptor signaling.

264 e F-BAR protein PACSIN2 in the regulation of EGF receptor signaling.

265 e cross-talk through indirect enhancement of EGF receptor signaling.

266 nctions to cause Dll to become responsive to EGF receptor signaling.

267 mesenchyme proliferation by sustaining Hbegf-EGF receptor signaling.

268 to drugs that block epidermal growth factor (EGF) receptor signaling could be caused by aberrant acti

269 n-regulated nuclear epidermal growth factor (EGF) receptor signaling in the CySC lineage is essential

270 etalloprotease 17), a principal regulator of EGF-receptor signaling and TNFalpha release, is rapidly

271 or ligand vein (vn), which further activates EGF receptor signalling and integrin expression non-cell

272 inly the JAK/STAT signalling pathway and the EGF receptor signalling pathway.

273 epithelial invasion by derepressing upstream EGF receptor, SRC tyrosine kinase, and phosphoinositide

274 Our findings reveal a novel link between EGF receptor stimulation, ILK-containing complexes, and

275 signaling via both the TGFbeta-receptor and EGF receptor suggesting that PAR2 utilizes transactivati

276 e F-BAR-domain protein PACSIN2 in regulating EGF receptor surface levels and EGF-induced downstream s

277 gulated by choline availability and controls EGF receptor synthesis and neurogenesis in the cerebral

278 For example, resistance to EGF receptor targeting occurs commonly, more so than was

279 nes increased endocytosis of transferrin and EGF receptors (TfR and EGFR) concurrent with motility an

280 mediated signaling, we generated a series of EGF receptors that contained only one tyrosine in their

281 lization at the plasma membrane of CD44, the EGF receptor, the ABCB1 and ABCG2 drug transporters, and

282 eting signaling via MET and CD44 during anti-EGF receptor therapy of patients with colorectal cancer

283 adapter proteins bound readily to wild-type EGF receptor, they bound poorly to the single-Tyr EGF re

284 aling axis is inhibited, the transit time of EGF receptor through early endosomes are accelerated, mi

285 how here that sSORLA binds and activates the EGF receptor to induce downstream signaling through the

286 r a MAPK signaling cascade downstream of the EGF receptor to investigate how interlinked positive and

287 gether, our studies reveal a crucial link of EGF receptor to NF-kappaB activation and tumor progressi

288 localization of the epidermal growth factor (EGF) receptor to the plasma membrane, prolonging EGF sig

289 1-dependent adaptive CME selectively altered EGF receptor trafficking, enhanced cell migration in vit

290 ents autocrine ligand shedding and resultant EGF receptor transactivation, it also leads to an accumu

291 internalized EGF as well as the (activated) EGF receptor translocated to PACSIN2-positive endosomes.

292 s to cell surface antigens including MET and EGF receptor, we have experimentally validated our model

293 Signals received via the EGF Receptor were necessary for the transience in Yan no

294 rb2, PI3K, p52 Shc, p66 Shc, and Shp2 to the EGF receptor when stimulated by the seven EGF receptor l

295 trikingly different from those of 5HT-2C and EGF receptors, which demonstrate the usefulness of the b

296 but require back-to-back dimerization of the EGF receptor with ErbB2.

297 binding to quantitate the interaction of the EGF receptor with ErbB2.

298 mulation was caused by marked endocytosis of EGF receptors with concomitant ERK attenuation, which st

299 activates non-receptor tyrosine kinases and EGF receptor, with a Src family kinase as a required int

300 veolae, leading to increased dimerization of EGF receptor within the confined surface area of caveola